Induction Chemotherapy

Patients with locoregionally advanced nasopharyngeal carcinoma may benefit from radiotherapy alone, result from a randomized phase 3 study suggest.

Induction chemotherapy with paclitaxel, cisplatin and capecitabine vs. cisplatin and fluorouracil improved failure-free survival among patients with advanced nasopharyngeal carcinoma, according to a study published in JAMA Oncology.

Radiotherapy after induction chemotherapy improved R0 circumferential resection margin-negative resection and pathologic complete response rates among patients with pancreatic cancer without a significant increase in R0 resection rate.

Maintenance therapy with oral azacitidine led to statistically significant and clinically meaningful improvements in OS and RFS among patients with acute myeloid leukemia in remission after induction chemotherapy.

Complete macroscopic excision of the primary tumor after induction chemotherapy appeared to improve survival outcomes among children with stage 4 high-risk neuroblastoma, according to study results published in Journal of Clinical Oncology.

An induction-concurrent chemotherapy sequence conferred a PFS benefit for patients with locoregionally advanced nasopharyngeal carcinoma treated with conventional fractionated radiotherapy, according to study results published in Cancer.

Response-adapted intensification treatment with a bortezomib-based regimen improved PFS among patients with newly diagnosed multiple myeloma who achieved minimal or partial response to immunomodulatory induction therapy, according to results of a randomized phase 3 study published in The Lancet Haematology.

ORLANDO — The oral hypomethylating agent CC-486 provided statistically significant and clinically meaningful improvements in OS and RFS for patients with acute myeloid leukemia in remission after induction chemotherapy, according to results of the randomized phase 3 QUAZAR AML-001 study presented during the late-breaking abstract session at ASH Annual Meeting and Exposition.